0IL8 Stock Chart & Stats
$7.33
-$0.27(-3.62%)
At close: 4:00 PM EDT
$7.33
-$0.27(-3.62%)
Day’s Range― - ―
52-Week Range$6.29 - $12.60
Previous CloseN/A
Volume211.00
Average Volume (3M)408.00
Market Cap
$28.50M
Enterprise Value-$38.76
Total Cash (Recent Filing)$91.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)0.1
Beta0.66
Next Earnings
Nov 09, 2026EPS Estimate
-3.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)58.19
Shares Outstanding4,048,112
10 Day Avg. Volume318
30 Day Avg. Volume408
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$32.50Price Target Upside343.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-13.75
Revenue Forecast (FY)$9.95M
Bulls Say, Bears Say
Bulls Say
Cash Runway Into 2028A $100.3M liquidity position with management guidance to fund operations into 2028 materially lowers near-term financing risk and gives the company time to reach key clinical inflection points. That runway supports executing trials and regulatory interactions without immediate capital raises.
Zero Debt Capital StructureHaving no debt eliminates interest expense and reduces default risk, providing flexibility to allocate capital to R&D and trial enrollment. This durable structural advantage makes funding choices cleaner and lowers the fixed-cost burden while clinical programs progress.
Clear Clinical Milestones And Biomarker StrategyDefined timelines for a Phase II interim readout and a planned Phase III start provide a visible development roadmap. Combined with FG-3180 PET biomarker work and constructive FDA feedback for roxadustat, this structured strategy can materially de-risk program design and improve prospects for a targeted Phase III.
Bears Say
Persistent Negative Operating Cash FlowConsistent negative operating and free cash flow indicates the business continues to burn cash to fund operations and development. Even with current reserves, continued negative OCF elevates refinancing risk, constrains optionality for parallel programs, and increases dependency on external funding.
Negative Shareholders' Equity In TTMNegative equity signals accumulated losses and reduces the balance-sheet cushion available to absorb further operating deficits. This structural weakness can hinder access to secured financing, complicate partnership negotiations, and raise long-term solvency concerns if losses persist.
Pipeline Dependent On Binary Clinical ReadoutsA significant portion of the company's future value hinges on upcoming trial outcomes and enrollment execution. Reliance on binary clinical readouts concentrates downside risk: missed endpoints, slow enrollment, or regulatory setbacks could materially reduce prospects and force strategic pivots or financing under duress.
Kyntra Bio News
0IL8 FAQ
What was Kyntra Bio, Inc.’s price range in the past 12 months?
Kyntra Bio, Inc. lowest share price was $6.29 and its highest was $12.60 in the past 12 months.
What is Kyntra Bio, Inc.’s market cap?
Kyntra Bio, Inc.’s market cap is $28.50M.
When is Kyntra Bio, Inc.’s upcoming earnings report date?
Kyntra Bio, Inc.’s upcoming earnings report date is Nov 09, 2026 which is in 85 days.
How were Kyntra Bio, Inc.’s earnings last quarter?
Kyntra Bio, Inc. released its earnings results on Aug 13, 2026. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of -$3.184 by $6.144.
Is Kyntra Bio, Inc. overvalued?
According to Wall Street analysts Kyntra Bio, Inc.’s price is currently Undervalued.
Does Kyntra Bio, Inc. pay dividends?
Kyntra Bio, Inc. pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Kyntra Bio, Inc. dividends here
What is Kyntra Bio, Inc.’s EPS estimate?
Kyntra Bio, Inc.’s EPS estimate is -3.66.
How many shares outstanding does Kyntra Bio, Inc. have?
Kyntra Bio, Inc. has 4,048,112 shares outstanding.
What happened to Kyntra Bio, Inc.’s price movement after its last earnings report?
Kyntra Bio, Inc. reported an EPS of $2.96 in its last earnings report, beating expectations of -$3.184. Following the earnings report the stock price went down -1.367%.
Which hedge fund is a major shareholder of Kyntra Bio, Inc.?
Currently, no hedge funds are holding shares in GB:0IL8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyntra Bio, Inc.
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
0IL8 Company Deck
0IL8 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful clinical and operational positives: concrete Phase I/IST efficacy signals for FG-3246 (with a clear plan for a Phase II interim readout in Q4 2026), a finalized Phase III protocol and compelling subgroup data for roxadustat, a unique non-PSMA therapeutic + companion diagnostic position, and a positive swing to net income with a cash runway into 2028. Offsetting these were notable near-term financial headwinds (negative reported revenue and higher operating expenses), safety and biomarker confirmation risks that require larger data sets, enrollment and market dynamics uncertainty (Pluvicto adoption) and the dependence on partnering/capital for a registrational path for roxadustat. On balance, the highlights modestly outweigh the lowlights due to actionable clinical progress and a forthcoming near-term catalyst (FG-3246 interim) alongside sufficient cash runway to advance programs.View all GB:0IL8 earnings summaries0IL8 Stock 12 Month Forecast
Average Price Target
$32.50
▲(343.38% Upside)
Technical Analysis
Grace Therapeutics
―
―
OnKure Therapeutics
―
Senti Biosciences
―
Xilio Therapeutics
―